Zydus and MSN launch first generic Adempas in US
In short
Zydus Lifesciences and MSN Laboratories launched riociguat tablets in the US after getting USFDA approval. The report says this is the first generic version of Adempas.
The launch could affect competition in the US medicine market, but the report does not give pricing or sales figures. It is still unknown how big the business impact will be.
What the reporting says
Zydus Lifesciences and MSN Laboratories launched riociguat tablets in the US after receiving USFDA approval, according to a publisher-supplied company summary. The report says the product is the first generic version of Adempas, but it does not state launch volumes, pricing or commercial terms. The immediate consequence is a potential competitive shift in the US market for this medicine.
Why it matters
Zydus Lifesciences and MSN Laboratories have launched riociguat tablets in the US after USFDA approval, and the publisher summary says this is the first generic Adempas. The reporting does not give launch economics, market share or sales estimates. The immediate relevance is to the companies’ US generic portfolios and to competition in the pulmonary hypertension treatment market.